Head and Neck Cancer Treatment Update: Pembrolizumab, Nivolumab and PD-L1 Markers

dbrock's picture
Jared Weiss, MD, Faculty and Board Vice President

Drs. Jared Weiss, Assistant Professor, Clinical Research Hematology/Oncology, University of North Carolina School of Medicine, and Josh Bauml, Assistant Professor of Medicine, Hospital of the University of Pennsylvania, join GRACE to discuss updates relating to pembrolizumab, nivolumab and PD-L1 markers for head and neck cancers.

 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation